Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon + GM-CSF vs GM-K562 Vaccine in CML
NCT00363649Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2006
- Primary completion
- Sep 2017
- Modality
- Cytokines & Interferons, Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GM-K562, interferon alfa, sargramostim in chronic myelogenous leukemia (CML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2006; status: completed.
02
Drugs
GM-K562interferon alfasargramostim
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00363649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363649.